TrialSignal
Clinical trial intelligence report
A Phase 2, Non-controlled, Open-Label, Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03216486
Status
WITHDRAWN
Phase
PHASE2
Sponsor
Ultragenyx Pharmaceutical Inc
Executive brief
Investment-Ready Snapshot
The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03216486
Indication
Osteogenesis Imperfecta
Modality
small molecule
Target
BPS804
Intervention
BPS804
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.